Atlas Venture Life Science Advisors, LLC Q1 2024 Filing

Filed May 6, 2024

Portfolio Value

$1.1T

Holdings

16

Report Date

Q1 2024

Filing Type

13F-HR

All Holdings (16 positions)

#StockSharesValue% PortfolioType
1
DYNDyne Therapeutics, Inc.
8,020,136$227.7B21.01%
2
KYMRKymera Therapeutics, Inc.
5,377,362$216.2B19.95%
3
IRONDisc Medicine, Inc.
2,287,233$142.4B13.14%
4
DAWNDay One Biopharmaceuticals, Inc.
6,430,257$106.2B9.80%
5
THRDThird Harmonic Bio, Inc.
10,907,859$103.0B9.50%
6
KRROKorro Bio, Inc.
1,119,292$100.7B9.30%
7
AVTEAerovate Therapeutics, Inc.
2,039,249$60.3B5.57%
8
QTTBQ32 Bio, Inc.
2,092,106$35.6B3.29%
9
GBIOGBXGeneration Bio, Co.
8,279,484$33.7B3.11%
10
VIGLVigil Neuroscience, Inc.
5,836,874$19.9B1.84%
11
REPLReplimune Group, Inc.
2,098,300$17.1B1.58%
12
Ikena Oncology, Inc.
5,018,178$7.1B0.66%
13
AvroBio, Inc.
4,541,381$5.8B0.54%
14
DNTHDianthus Therapeutics, Inc.
186,979$5.6B0.52%
15
XLOXilio Therapeutics, Inc.
992,912$1.1B0.10%
16
SPROSpero Therapeutics, Inc.
607,613$1.0B0.10%